Cyclacel(CYCC) - 2023 Q4 - Annual Results

Exhibit 99.1 CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – - Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, NJ, March 19, 2024 - Cyclacel Pharmaceuticals, I ...